Edwards Lifesciences CorporationEWNYSE
Loading
Book Value/Share Growth Recovery in ProgressRecovering
Percentile Rank38
5Y CAGR-24.6%
Year-over-Year Change
Year-over-year book value per share growth
5Y CAGR
-24.6%/yr
Long-term compound
Percentile
P38
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 2.05% |
| Q3 2025 | -3.41% |
| Q2 2025 | 4.05% |
| Q1 2025 | 1.78% |
| Q4 2024 | 6.01% |
| Q3 2024 | 29.12% |
| Q2 2024 | 4.34% |
| Q1 2024 | 7.59% |
| Q4 2023 | 0.18% |
| Q3 2023 | 4.34% |
| Q2 2023 | 6.45% |
| Q1 2023 | 5.32% |
| Q4 2022 | -5.56% |
| Q3 2022 | 4.80% |
| Q2 2022 | 1.89% |
| Q1 2022 | 0.48% |
| Q4 2021 | 5.23% |
| Q3 2021 | 7.72% |
| Q2 2021 | 10.35% |
| Q1 2021 | 1.89% |
| Q4 2020 | 8.40% |
| Q3 2020 | 7.45% |
| Q2 2020 | 0.85% |
| Q1 2020 | -5.69% |
| Q4 2019 | 8.43% |
| Q3 2019 | 8.95% |
| Q2 2019 | 1.42% |
| Q1 2019 | 9.88% |
| Q4 2018 | -6.17% |
| Q3 2018 | 6.48% |
| Q2 2018 | -2.19% |
| Q1 2018 | 8.69% |
| Q4 2017 | -5.08% |
| Q3 2017 | 7.18% |
| Q2 2017 | 7.54% |
| Q1 2017 | 5.96% |
| Q4 2016 | -2.93% |
| Q3 2016 | 8.42% |
| Q2 2016 | 7.93% |
| Q1 2016 | -6.98% |